[Federal Register Volume 89, Number 13 (Friday, January 19, 2024)]
[Notices]
[Pages 3663-3664]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01014]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2024-0003]


Meeting of the Advisory Committee to the Director, Centers for 
Disease Control and Prevention

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the 
Centers for Disease Control and Prevention (CDC) announces the 
following meeting for the Advisory Committee to the Director, Centers 
for Disease Control and Prevention (ACD, CDC). This is a hybrid 
meeting, accessible both in person and virtually (webcast live via the 
World Wide Web). It is open to the public and limited only by the space 
available. Time will be available for public comment.

DATES: The meeting will be held on February 21, 2024, from 9 a.m. to 3 
p.m., EST (times subject to change).
    Written comments must be received on or before February 5, 2024.

ADDRESSES: Meeting address: CDC Roybal Campus, Building 21, Room 1204 
A/B, 1600 Clifton Road NE, Atlanta, Georgia 30329-4027.
    Please note that the meeting location, the CDC Roybal Campus, is a 
federal facility and in-person access is limited to United States 
citizens unless prior authorizations, taking up to 30 to 60 days, have 
been made. Visitors must follow all directions for access to CDC 
facilities. Directions for visitors to CDC, including safety 
requirements related to COVID-19; are available at https://www.cdc.gov/screening/visitors.html.
    Registration: You must register to attend this meeting in person. 
If you wish to attend in person, please submit a request by email to 
[email protected] at least 5 business days in advance of the meeting. 
No registration is required to view the meeting via the World Wide Web. 
Information for accessing the webcast will be available at https://www.cdc.gov/about/advisory-committee-director/.
    Written comments: You may submit comments, identified by Docket No. 
CDC-2024-0003, by either of the following methods below. Do not submit 
comments for the docket by email. CDC does not accept comments for the 
docket by email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Kerry Caudwell, DPA, Centers for Disease Control and 
Prevention, 1600 Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 
30329-4027. Attn: Docket number CDC-2024-0003.
    Instructions: All submissions received must include the Agency name 
and Docket Number. All relevant comments received will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov. 
Written comments received in advance of the meeting will be included in 
the official record of the meeting.

FOR FURTHER INFORMATION CONTACT: Kerry Caudwell, D.P.A., Office of the 
Chief of Staff, Centers for Disease Control and Prevention, 1600 
Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 30329-4027, 
Telephone: (404) 639-0390; Email Address: [email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The Advisory Committee to the Director, CDC, shall (1) 
make recommendations to the Director regarding ways to prioritize the 
activities of the agency in alignment with the CDC Strategic Plan 
required under section 305(c); H.R. 2617-1252; (2) advise on ways to 
achieve or improve performance metrics in relation to the CDC Strategic 
Plan, and other relevant metrics, as appropriate; (3) provide advice 
and recommendations on the development of the Strategic Plan, and any 
subsequent updates, as appropriate; (4) advise on grant, cooperative 
agreements, contracts, or other transactions, as applicable; (5) 
provide other advice to the Director, as requested, to fulfill duties 
under sections 301 and 311; and (6) appoint subcommittees. The 
committee recommends ways to prioritize CDC's activities, improve 
results, and address health disparities. It also provides guidance to 
help CDC work more effectively with its various private and public 
sector constituents to make health protection a practical reality.
    Matters to be Considered: The agenda includes updates on CDC 
programs, Director's focus areas, and the Moving Forward Initiative. 
Agenda items are subject to change as priorities dictate.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: The docket will be opened to receive 
written comments on January 19, 2024 through February 5, 2024.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and

[[Page 3664]]

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-01014 Filed 1-18-24; 8:45 am]
BILLING CODE 4163-18-P